21 Jul 2025 Harm profile of JAK inhibitors in inflammatory rheumatic conditions
This report reviews open-label randomized and non-randomized experimental studies as well as observational studies of harm associated with the Janus kinase inhibitors (JAKi) tofacitinib and upadacitinib for the rheumatic conditions psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
Click on the ‘Download‘ button to view or download the report (PDF format).
No Comments